Cargando…

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed...

Descripción completa

Detalles Bibliográficos
Autores principales: Di, Jieyi, Zheng, Baotong, Kong, Qingfei, Jiang, Ying, Liu, Siyao, Yang, Yang, Han, Xudong, Sheng, Yuqi, Zhang, Yunpeng, Cheng, Liang, Han, Junwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763777/
https://www.ncbi.nlm.nih.gov/pubmed/31408580
http://dx.doi.org/10.1002/1878-0261.12564
_version_ 1783454270943657984
author Di, Jieyi
Zheng, Baotong
Kong, Qingfei
Jiang, Ying
Liu, Siyao
Yang, Yang
Han, Xudong
Sheng, Yuqi
Zhang, Yunpeng
Cheng, Liang
Han, Junwei
author_facet Di, Jieyi
Zheng, Baotong
Kong, Qingfei
Jiang, Ying
Liu, Siyao
Yang, Yang
Han, Xudong
Sheng, Yuqi
Zhang, Yunpeng
Cheng, Liang
Han, Junwei
author_sort Di, Jieyi
collection PubMed
description Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of candidate drugs (PriorCD), for the prioritization of candidate cancer drugs based on a global network propagation algorithm and a drug–drug functional similarity network constructed by integrating pathway activity profiles and drug activity profiles. This provides a new approach to drug repurposing by first considering the drug functional similarities at the pathway level. The performance of PriorCD in drug repurposing was evaluated by using drug datasets of breast cancer and ovarian cancer. Cross‐validation tests on the drugs approved for the treatment of these cancers indicated that our approach can achieve area under receiver‐operating characteristic curve (AUROC) values greater than 0.82. Furthermore, literature searches validated our results, and comparison with other classical gene‐based repurposing methods indicated that our pathway‐level PriorCD is comparatively more effective at prioritizing candidate drugs with similar therapeutic effects. We hope that our study will be of benefit to the field of drug discovery. In order to expand the usage of PriorCD, a freely available R‐based package, PriorCD, has been developed to prioritize candidate anticancer drugs for drug repurposing.
format Online
Article
Text
id pubmed-6763777
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67637772019-10-01 Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities Di, Jieyi Zheng, Baotong Kong, Qingfei Jiang, Ying Liu, Siyao Yang, Yang Han, Xudong Sheng, Yuqi Zhang, Yunpeng Cheng, Liang Han, Junwei Mol Oncol Research Articles Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of candidate drugs (PriorCD), for the prioritization of candidate cancer drugs based on a global network propagation algorithm and a drug–drug functional similarity network constructed by integrating pathway activity profiles and drug activity profiles. This provides a new approach to drug repurposing by first considering the drug functional similarities at the pathway level. The performance of PriorCD in drug repurposing was evaluated by using drug datasets of breast cancer and ovarian cancer. Cross‐validation tests on the drugs approved for the treatment of these cancers indicated that our approach can achieve area under receiver‐operating characteristic curve (AUROC) values greater than 0.82. Furthermore, literature searches validated our results, and comparison with other classical gene‐based repurposing methods indicated that our pathway‐level PriorCD is comparatively more effective at prioritizing candidate drugs with similar therapeutic effects. We hope that our study will be of benefit to the field of drug discovery. In order to expand the usage of PriorCD, a freely available R‐based package, PriorCD, has been developed to prioritize candidate anticancer drugs for drug repurposing. John Wiley and Sons Inc. 2019-08-21 2019-10 /pmc/articles/PMC6763777/ /pubmed/31408580 http://dx.doi.org/10.1002/1878-0261.12564 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Di, Jieyi
Zheng, Baotong
Kong, Qingfei
Jiang, Ying
Liu, Siyao
Yang, Yang
Han, Xudong
Sheng, Yuqi
Zhang, Yunpeng
Cheng, Liang
Han, Junwei
Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
title Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
title_full Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
title_fullStr Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
title_full_unstemmed Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
title_short Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
title_sort prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763777/
https://www.ncbi.nlm.nih.gov/pubmed/31408580
http://dx.doi.org/10.1002/1878-0261.12564
work_keys_str_mv AT dijieyi prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT zhengbaotong prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT kongqingfei prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT jiangying prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT liusiyao prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT yangyang prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT hanxudong prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT shengyuqi prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT zhangyunpeng prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT chengliang prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities
AT hanjunwei prioritizationofcandidatecancerdrugsbasedonadrugfunctionalsimilaritynetworkconstructedbyintegratingpathwayactivitiesanddrugactivities